EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma

Mostrar otras versiones (1)

On August 28, 2015, a marketing authorization valid through the European Union was issued for panobinostat, in combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including b...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzogani, Kyriaki, van Hennik, Paula, Walsh, Ita, De Graeff, Pieter, Folin, Annika, Sjöberg, Jan, Salmonson, Tomas, Bergh, Jonas, Laane, Edward, Ludwig, Heinz, Gisselbrecht, Christian, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Regulatory Issues: EMA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947444/
https://www.ncbi.nlm.nih.gov/pubmed/29192015
http://dx.doi.org/10.1634/theoncologist.2017-0301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947444/
https://www.ncbi.nlm.nih.gov/pubmed/29192015
http://dx.doi.org/10.1634/theoncologist.2017-0301

Ejemplares similares